HC Wainwright Issues Positive Estimate for BCYC Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Analysts at HC Wainwright raised their Q1 2025 earnings estimates for shares of Bicycle Therapeutics in a research report issued to clients and investors on Monday, December 16th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.93) per share for the quarter, up from their previous estimate of ($0.99). HC Wainwright currently has a "Buy" rating and a $33.00 target price on the stock. The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Bicycle Therapeutics' Q2 2025 earnings at ($0.96) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($4.14) EPS, FY2027 earnings at ($3.49) EPS and FY2028 earnings at ($2.12) EPS.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.04. The firm had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company's revenue for the quarter was down 50.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.26) earnings per share.

Several other equities analysts also recently issued reports on the company. JMP Securities cut their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a research report on Wednesday. Stephens started coverage on Bicycle Therapeutics in a report on Friday, November 8th. They issued an "equal weight" rating and a $25.00 price target for the company. Royal Bank of Canada reissued an "outperform" rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. Needham & Company LLC restated a "buy" rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Bicycle Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $35.25.

Bicycle Therapeutics Price Performance

Shares of BCYC traded down $0.31 on Thursday, hitting $15.00. The company's stock had a trading volume of 475,140 shares, compared to its average volume of 404,501. The company has a market capitalization of $1.04 billion, a PE ratio of -4.56 and a beta of 0.86. Bicycle Therapeutics has a fifty-two week low of $12.17 and a fifty-two week high of $28.67. The company has a 50 day moving average price of $22.27 and a 200 day moving average price of $22.61.

Insider Activity

In related news, Director Bros. Advisors Lp Baker purchased 985,397 shares of the business's stock in a transaction dated Friday, December 13th. The shares were bought at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the purchase, the director now directly owns 9,537,643 shares in the company, valued at $131,237,967.68. This trade represents a 11.52 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kevin Lee sold 3,212 shares of the firm's stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the transaction, the chief executive officer now owns 380,864 shares in the company, valued at $8,478,032.64. This represents a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,840 shares of company stock valued at $259,128. 8.50% of the stock is currently owned by insiders.

Institutional Trading of Bicycle Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC boosted its stake in Bicycle Therapeutics by 17.9% during the 2nd quarter. Armistice Capital LLC now owns 1,972,000 shares of the company's stock worth $39,913,000 after acquiring an additional 300,000 shares during the last quarter. Westfield Capital Management Co. LP raised its holdings in Bicycle Therapeutics by 21.5% in the third quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company's stock worth $41,887,000 after purchasing an additional 327,089 shares during the period. First Light Asset Management LLC boosted its position in shares of Bicycle Therapeutics by 16.1% during the second quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company's stock worth $28,028,000 after purchasing an additional 191,717 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Bicycle Therapeutics by 1,438.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company's stock valued at $20,362,000 after buying an additional 841,299 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Bicycle Therapeutics by 0.6% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company's stock valued at $17,975,000 after buying an additional 4,976 shares in the last quarter. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.